Dulaglutide
Also known as: LY2189265, Trulicity
Classification
Peptide
Regulatory Status
FDA-approved prescription product
Sources
2
Review
n/a
Overview
Dulaglutide is a once-weekly GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, reduces glucagon, and slows gastric emptying, improving glycemic control in type 2 diabetes.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
Benefits
FDA-approved as an adjunct to diet and exercise to improve glycemic control in eligible patients with type 2 diabetes.
Labeled to reduce major adverse cardiovascular events in adults with type 2 diabetes and cardiovascular disease or multiple risk factors, supported by outcomes evidence including REWIND.
Interactions & cautions
Flagged in source data
other GLP-1 or dual incretin agonists without prescriber rationale
Drug interactions
insulin or insulin secretagogues — Increased hypoglycemia potential versus dulaglutide alone. (review)
oral medications requiring threshold concentrations — May alter absorption kinetics of some oral drugs. (review)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw